PAUL ANDREA (General Counsel) received a stock award from ZENTALIS PHARMACEUTICALS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 2/1/2023ACC: 0001725160-23-000016
Officer· General Counsel
Since Aug 2022
+100K
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
2
Total transactions
100K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+40.78K
Price / share
—
Trade value
—
% of position
New position
2/1/2023
0.00→40.78K
Total
Net shares
+40.78K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/1/2023 | A · Award | +40.78K | — | — | New position | 0.00 | 40.78K |
| Total | +40.78K | $0.00 | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
59.22K shares
Shares
+59.22K
Strike price
23.65
Held after
59.22K
Exercisable
—
2/1/2023
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock59.22K shares | 2/1/2023 | A · Award | +59.22K | 23.65 | — | 59.22K |